Cas12 proteins and uses thereof
AssigneesReforgene Medicine, Zhejiang Synsorbio Technology Co., Ltd.
InventorsJunbin LIANG, Liancheng HUANG, Chongjian CHEN, Yang SUN, Weiye PAN, Hui XU, Kaiwei SI, Jinxiu CAI, Qing LIAO, Desheng HUANGFU
Life of this patent
Estimating the term…
Abstract
Cas12 protein, guide polynucleotide, inactivated Cas12 mutant, fusion protein or conjugate including the Cas12 protein, isolated nucleic acid, CRISPR-Cas12 system, vector system, delivery system, cell, pharmaceutical composition, and kit, and the use thereof are provided.
Claims20
A non-naturally occurring Cas12 protein, wherein the Cas12 protein comprises the amino acid sequence having at least 80% sequence identity to the amino acid sequence shown in SEQ ID NO:
- 696, wherein the Cas12 protein has one or more mutations relative to the amino acid sequence shown in SEQ ID NO:
- 696.
A fusion protein or conjugate, comprising:
- (1) a Cas12 protein, wherein the Cas12 protein comprises an amino acid sequence having at least 80% sequence identity to the amino acid sequence shown in SEQ ID NO:
- 696;
- and
- (2) a homologous or heterologous functional domain.
A CRISPR-Cas12 system, comprising:
- a. a fusion protein comprising a Cas12 protein, wherein the Cas12 protein comprises an amino acid sequence having at least 80% sequence identity to the amino acid sequence shown in SEQ ID NO:
- 696, or an isolated nucleic acid encoding the fusion protein;
- and
- b. a guide polynucleotide, or a polynucleotide sequence encoding the guide polynucleotide;
- wherein the fusion protein forms a complex with the guide polynucleotide;
- and the guide polynucleotide comprises a guide sequence engineered to guide a sequence-specific binding of the complex to a target nucleic acid.
Dependencies are inferred from the claim text.